Abstract
Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension are important and frequently under recognized conditions. This article provides an overview of key highlights in pulmonary vascular diseases from the 2023 ERS congress. This includes insights into disease modification in pulmonary arterial hypertension and novel therapies such as sotatercept, and seralutinib. Exciting developments in our understanding of the mechanisms underpinning pulmonary hypertension associated with interstitial lung disease are also explored. A comprehensive overview of the complex relationship between acute pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) is provided and our current understanding of the molecular determinants of CTEPH. The importance of multidisciplinary and holistic care cannot be understated, and this article also addresses advances beyond medication, with a special focus on exercise training and rehabilitation.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of Interest: Sarah Cullivan: reports travel grant form Janssen outside the submitted work.
Conflict of Interest: Athenais Boucly: has conflicts of interest with AOP Orphan, Janssen, Ferrer and MSD outside the submitted work.
Conflict of Interest: Mitja Jevnikar: reports travel grants from MSD, Janssen, Astrazeneca and consulting fees from Janssen outside the submitted work.
Conflict of Interest: Benoit Lechatier: has conflicts of interest with MSD and Janssen for advisory board and travel grants outside the submitted work.
Conflict of Interest: Silvia Ulrich: S. U. receives grant money from the Swiss National Science Foundation, Zurich and Swiss Lung League. S. U. received grant money, travel fees, consultancy and for patient enrolment into trials from Janssen SA, Switzerland, MSD SA, Switzerland, Novartis SA Switzerland and OrPha-Swiss, Switzerland.
Conflict of Interest: Laurent Bertoletti: personal fees and non-financial support from BMS/PFIZER, personal fees and non-financial support from LEO-Pharma, personal fees and non-financial support from VIATRIS, grants from BAYER, grants, personal fees and non-financial support from MSD, outside the submitted work; .
Conflict of Interest: Olivier Sitbon: relationships with pharmaceutical companies including Merck, Janssen, Enzyvant, Gossamer Bio, Respira Therapeutics, Ferrer and AOP Orphan, outside the submitted work. Relationships include grants for research and educational programs, fees for lectures and membership of scientific advisory boards.
Conflict of Interest: Anton Vonk-Noordegraaf: Advisory boards for Ferrer, MSD, Johnson&Johnson outside the submitted work.
Conflict of Interest: Leon Genecand: nothing to declare
Conflict of Interest: Julien Guiot reports grants paid to his institution from Roche, Janssen, Merk, consulting fees from Oncoradiomics, Janssen, Boeringer Ingelheim, Pfizer, Astrazeneca and honoraria from Janssen, SMB, GSK and Chiesi and travel support from Merck and Chiesi, all outside the submitted work.
Conflict of Interest: Etienne-Marie Jutant reports consulting fees from Chiesi, honoraria from Chiesi, GSK, MSD and Astrazeneca and travel support from Janssen and MSD.
Conflict of Interest: Lucilla Piccari reports grants from Janssen and Ferrer, lecture honoraria from Janssen, Ferrer, MSD and United Therapeutics, participation on advisory boards with Janssen, Ferrer and United Therapeutics, and travel support from Janssen, Ferrer and MSD, outside the submitted work.
Conflict of Interest: Mona Lichtblau reports travel support, lecture honoraria and participation on advisory boards from Janssen, MSD and Orpha Swiss, outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received November 1, 2023.
- Accepted November 2, 2023.
- Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
